BR112022015626A2 - Composição e métodos de vacinas de mrna contra infecção de novo coronavírus - Google Patents
Composição e métodos de vacinas de mrna contra infecção de novo coronavírusInfo
- Publication number
- BR112022015626A2 BR112022015626A2 BR112022015626A BR112022015626A BR112022015626A2 BR 112022015626 A2 BR112022015626 A2 BR 112022015626A2 BR 112022015626 A BR112022015626 A BR 112022015626A BR 112022015626 A BR112022015626 A BR 112022015626A BR 112022015626 A2 BR112022015626 A2 BR 112022015626A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- mrna
- composition
- mrna vaccines
- vaccines against
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 108700021021 mRNA Vaccine Proteins 0.000 title abstract 3
- 229940126582 mRNA vaccine Drugs 0.000 title abstract 3
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 2
- 239000000969 carrier Substances 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 108700005077 Viral Genes Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971834P | 2020-02-07 | 2020-02-07 | |
| US202063058463P | 2020-07-29 | 2020-07-29 | |
| US202063130581P | 2020-12-24 | 2020-12-24 | |
| PCT/US2021/017149 WO2021159118A2 (en) | 2020-02-07 | 2021-02-08 | Composition and method of mrna vaccines against novel coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015626A2 true BR112022015626A2 (pt) | 2022-10-11 |
Family
ID=77200778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015626A BR112022015626A2 (pt) | 2020-02-07 | 2021-02-08 | Composição e métodos de vacinas de mrna contra infecção de novo coronavírus |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12029786B2 (https=) |
| EP (1) | EP4100066A4 (https=) |
| JP (1) | JP2023512833A (https=) |
| KR (1) | KR20220143684A (https=) |
| CN (1) | CN115297892A (https=) |
| AU (1) | AU2021216443A1 (https=) |
| BR (1) | BR112022015626A2 (https=) |
| CA (1) | CA3167257A1 (https=) |
| IL (1) | IL295360A (https=) |
| MX (1) | MX2022009688A (https=) |
| WO (1) | WO2021159118A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| WO2021160887A1 (en) * | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| JPWO2021181994A1 (https=) * | 2020-03-10 | 2021-09-16 | ||
| US20230313323A1 (en) * | 2020-03-26 | 2023-10-05 | Ionian Technologies, Llc | Assays for detecting coronavirus disease 2019 (covid-19) |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| EP4334479A4 (en) * | 2021-05-06 | 2025-02-19 | Lu, Shi-Long | DETECTION OF VIRAL VARIANTS |
| JP2024530672A (ja) | 2021-08-11 | 2024-08-23 | アールエヌエーイミューン、インコーポレイテッド | 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN118475371A (zh) * | 2021-09-22 | 2024-08-09 | 圣诺制药公司 | 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂 |
| WO2023049814A2 (en) * | 2021-09-22 | 2023-03-30 | Sirnaomics, Inc. | Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index |
| CN113881806A (zh) * | 2021-09-23 | 2022-01-04 | 华南理工大学 | 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒 |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| WO2023091766A2 (en) * | 2021-11-19 | 2023-05-25 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| AU2022398292A1 (en) * | 2021-11-29 | 2024-06-13 | BioNTech SE | Coronavirus vaccine |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN118556131A (zh) | 2022-01-27 | 2024-08-27 | 爱思开生物科技有限公司 | 用于蛋白质表达的mRNA及其模板 |
| US20250228929A1 (en) * | 2022-04-03 | 2025-07-17 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| DE102023002588A1 (de) * | 2022-06-26 | 2024-01-25 | BioNTech SE | Coronavirus-Impfstoff |
| WO2024002985A1 (en) * | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| KR102832944B1 (ko) * | 2024-12-27 | 2025-07-15 | 대한민국 | 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1270732A1 (en) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| SG11201405542UA (en) * | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| CN110520155A (zh) * | 2017-02-28 | 2019-11-29 | 广州纳泰生物医药技术有限公司 | 预防和治疗寨卡病毒感染的rna药物制剂 |
| AU2019275071B2 (en) * | 2018-05-24 | 2022-12-15 | Sirnaomics, Inc. | Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics |
| PH12022551788A1 (en) * | 2020-01-28 | 2024-02-26 | Codagenix Inc | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| US20210316002A1 (en) | 2020-04-14 | 2021-10-14 | Ut-Battelle, Llc | Compositions and methods for drug delivery and treating viral infections |
| BR112022024662A2 (pt) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 |
| EP4204015A4 (en) | 2020-08-31 | 2025-01-01 | The Board of Trustees of the Leland Stanford Junior University | Systems and methods for producing rna constructs with increased translation and stability |
| US20250213679A1 (en) | 2020-10-02 | 2025-07-03 | Celsion Corporation | Polynucleotide vaccines and methods of using the same |
| CN115160413B (zh) | 2021-04-06 | 2023-11-14 | 清华大学 | 一种新型冠状病毒疫苗 |
-
2021
- 2021-02-08 US US17/170,876 patent/US12029786B2/en active Active
- 2021-02-08 BR BR112022015626A patent/BR112022015626A2/pt not_active Application Discontinuation
- 2021-02-08 US US17/798,051 patent/US20230108926A1/en not_active Abandoned
- 2021-02-08 EP EP21750867.0A patent/EP4100066A4/en not_active Withdrawn
- 2021-02-08 CN CN202180024212.1A patent/CN115297892A/zh active Pending
- 2021-02-08 WO PCT/US2021/017149 patent/WO2021159118A2/en not_active Ceased
- 2021-02-08 IL IL295360A patent/IL295360A/en unknown
- 2021-02-08 KR KR1020227030556A patent/KR20220143684A/ko not_active Withdrawn
- 2021-02-08 CA CA3167257A patent/CA3167257A1/en active Pending
- 2021-02-08 MX MX2022009688A patent/MX2022009688A/es unknown
- 2021-02-08 JP JP2022548143A patent/JP2023512833A/ja active Pending
- 2021-02-08 AU AU2021216443A patent/AU2021216443A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021159118A3 (en) | 2021-10-28 |
| IL295360A (en) | 2022-10-01 |
| EP4100066A4 (en) | 2024-05-01 |
| JP2023512833A (ja) | 2023-03-29 |
| KR20220143684A (ko) | 2022-10-25 |
| CA3167257A1 (en) | 2021-08-12 |
| US12029786B2 (en) | 2024-07-09 |
| WO2021159118A2 (en) | 2021-08-12 |
| MX2022009688A (es) | 2022-12-15 |
| CN115297892A (zh) | 2022-11-04 |
| US20230108926A1 (en) | 2023-04-06 |
| US20220040292A1 (en) | 2022-02-10 |
| EP4100066A2 (en) | 2022-12-14 |
| AU2021216443A1 (en) | 2022-09-08 |
| WO2021159118A8 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015626A2 (pt) | Composição e métodos de vacinas de mrna contra infecção de novo coronavírus | |
| BR112022024248A2 (pt) | Vacinas de combinação à base de ácido nucleico | |
| WO2022043551A3 (en) | Multivalent nucleic acid based coronavirus vaccines | |
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| BR112022016507A2 (pt) | Vacinas contra o coronavírus e métodos de uso | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| BR112022014578A2 (pt) | Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov) | |
| BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| RU2013114392A (ru) | Маленькие липосомы для доставки кодирующей иммуноген рнк | |
| HRP20141125T1 (hr) | Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| RU2014134365A (ru) | Вакцины против clostridium difficile, включающие рекомбинантные токсины | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| MX2020001402A (es) | Metodos de terapia genica del factor viii (fviii). | |
| BR112023000220A2 (pt) | Formulações de longa ação | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112022026874A2 (pt) | Substância farmacêutica, uso, método de proteção de um indivíduo e vacina | |
| BR112023021654A2 (pt) | Vacina contra vírus | |
| DE60331412D1 (de) | Hiv-vakzine und anwendungsverfahren | |
| Gudadappanavar et al. | An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario | |
| WO2022103929A3 (en) | Nucleic acids, proteins, and vaccines of sars-cov-2 | |
| WO2023108083A3 (en) | Nanoparticle immunogenic compositions and vaccination methods | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |